NasdaqCM - Nasdaq Real Time Price USD

Champions Oncology, Inc. (CSBR)

5.07 +0.01 (+0.20%)
At close: April 23 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
4/30/2023
4/30/2022
4/30/2021
4/30/2020
Total Revenue
49,224.00
53,870.00
49,109.00
41,040.00
32,123.00
Cost of Revenue
29,489.00
29,532.00
23,632.00
21,446.00
17,000.00
Gross Profit
19,735.00
24,338.00
25,477.00
19,594.00
15,123.00
Operating Expense
28,534.00
28,787.00
24,870.00
19,228.00
16,709.00
Operating Income
-8,799.00
-4,449.00
607.00
366.00
-1,586.00
Other Income Expense
-860.00
-818.00
-24.00
71.00
-377.00
Pretax Income
-9,659.00
-5,267.00
583.00
437.00
-1,963.00
Tax Provision
69.00
68.00
35.00
75.00
130.00
Net Income Common Stockholders
-9,728.00
-5,335.00
548.00
362.00
-2,093.00
Diluted NI Available to Com Stockholders
-9,728.00
-5,335.00
548.00
362.00
-2,093.00
Basic EPS
-0.72
-0.39
0.04
0.03
-0.18
Diluted EPS
-0.72
-0.39
0.04
0.02
-0.18
Basic Average Shares
13,545.68
13,541.56
13,197.17
13,139.00
11,843.46
Diluted Average Shares
13,545.68
13,541.56
14,159.80
14,573.56
11,843.46
Total Operating Income as Reported
-9,606.00
-5,256.00
607.00
366.00
-1,921.00
Total Expenses
58,023.00
58,319.00
48,502.00
40,674.00
33,709.00
Net Income from Continuing & Discontinued Operation
-9,728.00
-5,335.00
548.00
362.00
-2,093.00
Normalized Income
-9,243.80
-4,697.47
548.00
362.00
-1,848.45
EBIT
-8,799.00
-4,449.00
607.00
366.00
-1,586.00
EBITDA
-6,806.00
-2,203.00
2,234.00
1,550.00
-761.00
Reconciled Cost of Revenue
29,489.00
29,532.00
23,632.00
21,446.00
17,000.00
Reconciled Depreciation
1,993.00
2,246.00
1,627.00
1,184.00
825.00
Net Income from Continuing Operation Net Minority Interest
-9,728.00
-5,335.00
548.00
362.00
-2,093.00
Total Unusual Items Excluding Goodwill
-807.00
-807.00
--
--
-335.00
Total Unusual Items
-807.00
-807.00
--
--
-335.00
Normalized EBITDA
-5,999.00
-1,396.00
2,234.00
1,550.00
-426.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-322.80
-169.47
--
--
-90.45
4/30/2020 - 2/2/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SABSW SAB Biotherapeutics, Inc.
0.0300
0.00%
 
XBIOW Xenetic Biosciences, Inc.
7.46
-17.11%
 
ARTLW Artelo Biosciences, Inc.
0.0117
0.00%
 
BCDAW BioCardia, Inc.
0.0219
-18.28%
 
JSPRW Jasper Therapeutics, Inc.
0.1200
-23.57%
 
ANEB Anebulo Pharmaceuticals, Inc.
2.7100
+2.26%
 
LEXXW Lexaria Bioscience Corp.
0.7600
-6.17%
 
CMRA Comera Life Sciences Holdings, Inc.
0.0410
0.00%
 
ESLA Estrella Immunopharma, Inc.
1.0300
+1.98%
 
EMMA Emmaus Life Sciences, Inc.
0.0921
0.00%